PAK4 shRNA Plasmid (h) from Santa Cruz Biotechnology, Inc. | Biocompare.com

Supplier Images

PAK4 shRNA Plasmid (h)

Be the first to write a review!

Citations:

Supplier Page from
Santa Cruz Biotechnology, Inc. for
PAK4 shRNA Plasmid (h)

Product Specs
ItemPAK4 shRNA Plasmid (h)
CompanySanta Cruz Biotechnology, Inc.
Price $592.00Supplier Page View Company Product Page
Catalog Numbersc-39060-SH
Quantity20 µg
RNA TypeshRNA Clones
Vector Type (Standardized)Lentiviral
NCBI Full Gene Namep21 (RAC1) activated kinase 4
Specieshuman
TypeshRNA Plasmid

Add to Compare List

Santa Cruz Biotechnology, Inc.

Santa Cruz Biotechnology, Inc.

10410 Finnell Street

Dallas, Texas 75220

United States

Phone: 1-800-457-3801
831-457-3801

Company Profile

Website: http://www.scbt.com/

(1) Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-Bad-microRNA drug resistance axis leading to inhibition of pancreatic ductal adenocarcinoma proliferationSmall GTPasesSeptember 1, 2019Mohammad RM, Li Y, Muqbil I, Aboukameel A, Senapedis W, Baloglu E, Landesman Y, Philip PA, Azmi AS.

(2) MiR-199a-3p decreases esophageal cancer cell proliferation by targeting p21 activated kinase 4OncotargetJune 19, 2018Phatak P, Burrows WM, Chesnick IE, Tulapurkar ME, Rao JN, Turner DJ, Hamburger AW, Wang JY, Donahue JM.

(3) MiR-199a/b-3p inhibits gastric cancer cell proliferation via down-regulating PAK4/MEK/ERK signaling pathwayBMC cancerJanuary 5, 2018Zeng B, Shi W, Tan G.

(4) A novel interaction of PAK4 with PPARγ to regulate Nox1 and radiation-induced epithelial-to-mesenchymal transition in gliomaOncogeneSeptember 14, 2017Kesanakurti D, Maddirela D, Banasavadi-Siddegowda YK, Lai TH, Qamri Z, Jacob NK, Sampath D, Mohanam S, Kaur B, Puduvalli VK.

(5) Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal AdenocarcinomaMolecular cancer therapeuticsJanuary 1, 2017Aboukameel A, Muqbil I, Senapedis W, Baloglu E, Landesman Y, Shacham S, Kauffman M, Philip PA, Mohammad RM, Azmi AS.

(6) PAK4 confers the malignance of cervical cancers and contributes to the cisplatin-resistance in cervical cancer cells via PI3K/AKT pathwayDiagnostic pathologySeptember 28, 2015Shu XR, Wu J, Sun H, Chi LQ, Wang JH.

(7) MicroRNA-433 inhibits cell proliferation in hepatocellular carcinoma by targeting p21 activated kinase (PAK4)Molecular and cellular biochemistryJanuary 1, 2015Xue J, Chen LZ, Li ZZ, Hu YY, Yan SP, Liu LY.

(8) PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathwaysBioscience reportsApril 1, 2014Fu X, Feng J, Zeng D, Ding Y, Yu C, Yang B.

(9) Identification of PAK4 as a putative target gene for amplification within 19q13.12-q13.2 in oral squamous-cell carcinomaCancer scienceOctober 1, 2009Begum A, Imoto I, Kozaki K, Tsuda H, Suzuki E, Amagasa T, Inazawa J.

Be the First to Write a Review!